阿尔茨海默病淀粉样β 1-42、p-tau 和 t-tau 检测分析。
Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.
机构信息
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Neurology and Alzheimer Center Amsterdam UMC, Amsterdam, the Netherlands.
出版信息
Alzheimers Dement. 2022 Apr;18(4):635-644. doi: 10.1002/alz.12406. Epub 2021 Jul 26.
INTRODUCTION
We aimed to provide cut points for the automated Elecsys Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers.
METHODS
Cut points for Elecsys amyloid beta 42 (Aβ42), total tau (t-tau), hyperphosphorylated tau (p-tau), and t-tau/Aβ42 and p-tau/Aβ42 ratios were evaluated in Mayo Clinic Study of Aging (n = 804) and Mayo Clinic Alzheimer's Disease Research Center (n = 70) participants.
RESULTS
The t-tau/Aβ42 and p-tau/Aβ42 ratios had a higher percent agreement with normal/abnormal amyloid positron emission tomography (PET) than the individual CSF markers. Reciever Operating Characteristic (ROC)-based cut points were 0.26 (0.24-0.27) for t-tau/Aβ42 and 0.023 (0.020-0.025) for p-tau/Aβ42. Ratio cut points derived from other cohorts performed as well in our cohort as our own did. Individual biomarkers had worse diagnostic properties and more variable results in terms of positive and negative percent agreement (PPA and NPA).
CONCLUSION
CSF t-tau/Aβ42 and p-tau/Aβ42 ratios are very robust indicators of AD. For individual biomarkers, the intended use should determine which cut point is chosen.
简介
我们旨在为 Elecsys 阿尔茨海默病（AD）脑脊液（CSF）生物标志物的自动分析提供切点。
方法
在 Mayo 诊所衰老研究（n=804）和 Mayo 诊所阿尔茨海默病研究中心（n=70）参与者中，评估 Elecsys 淀粉样蛋白β 42（Aβ42）、总 tau（t-tau）、磷酸化 tau（p-tau）以及 t-tau/Aβ42 和 p-tau/Aβ42 比值的切点。
结果
与单个 CSF 标志物相比，t-tau/Aβ42 和 p-tau/Aβ42 比值与正常/异常淀粉样 PET 的一致性更高。基于接收者操作特征（ROC）的切点为 t-tau/Aβ42 为 0.26（0.24-0.27），p-tau/Aβ42 为 0.023（0.020-0.025）。来自其他队列的比值切点在我们的队列中的表现与我们自己的一样好。个体生物标志物在阳性和阴性百分比一致（PPA 和 NPA）方面具有较差的诊断特性和更多的可变结果。
结论
CSF t-tau/Aβ42 和 p-tau/Aβ42 比值是 AD 的非常可靠指标。对于个体生物标志物，预期用途应确定选择哪个切点。
Zotero 插件